418
Participants
Start Date
July 31, 2017
Primary Completion Date
December 22, 2017
Study Completion Date
January 16, 2018
HTX-011
HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
Bupivacaine HCl
Bupivacaine HCl without epinephrine, 75 mg by injection
Saline placebo
Saline placebo by instillation
Luer-lock applicator
Applicator for instillation
Vial access device
Device for withdrawal of drug product
Jessa Ziekenhuis, Hasselt
Ziekenhuis Oost Limburg, Genk
Cornerstone Research Institute, LLC, Longwood
Park Place Surgery Center, Maitland
University of Miami, Miami
Eliza Coffee Memorial Hospital, Florence
Shoals Medical Trials, Inc., Sheffield
Midwest Clinical Research, Dayton
St. Louis Clinical Trials, St Louis
Plano Surgical Hospital, Plano
Hermann Drive Surgical Hospital, Houston
Westside Surgical Hospital, Houston
Endeavor Clinical Trials, P.A., San Antonio
EPIC Medical Research, LLC, Murray
Jean Brown Research, Salt Lake City
Arizona Research Center, Phoenix
eStudySite, Las Vegas
American Institute of Research, Whittier
Lotus Clinical Research, LLC, Pasadena
HD Research Corp, Riverside
Alliance Research Centers, Laguna Hills
Anaheim Clinical Trials, LLC, Anaheim
Trovare Clinical Research, Inc., Bakersfield
Yale University School of Medicine, New Haven
Lead Sponsor
Heron Therapeutics
INDUSTRY